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Summary: In the large community-based SCOOP trial, systematic fracture risk screening using FRAX® 2 
led to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual 3 
care.  4 
 5 
Purpose: In the SCreening of Older wOmen for Prevention of fracture’ (SCOOP) trial we investigated 6 
the effect of the screening intervention on subsequent long-term self-reported adherence to 7 
antiosteoporosis medications(AOM). 8 
Methods: SCOOP was a primary care-based UK multi-centre trial of screening for fracture risk. 12,483 9 
women (70-85years) were randomised to either usual NHS care, or assessment using the FRAX® tool 10 
+/- dual-energy X-ray absorptiometry(DXA), with medication recommended for those found to be at 11 
high risk of hip fracture. Self-reported AOM use was obtained by postal questionnaires at 6, 12, 24, 12 
36, 48 and 60 months. Analysis was limited to those who initiated AOM during follow-up.  Logistic 13 
regression was used to explore baseline determinants of adherence(good>=80%; poor<80%). 14 
Results: The mean (SD) age of participants was 75.6 (4.2) years, with 6233 randomised to screening 15 
and 6250 to the control group.  Of those participants identified at high fracture risk in the screening 16 
group, 38.2% of those on treatment at 6 months were still treated at 60 months; whereas the 17 
corresponding figure for the control group was 21.6%. Older age was associated with poorer 18 
adherence [OR per year increase in age 0.96 (95%CI: 0.93, 0.99), p=0.01], whereas history of parental 19 
hip fracture was associated with greater rates adherence [OR 1.67 (95%CI: 1.23, 2.26), p<0.01]. 20 
Conclusions: Systematic fracture risk screening using FRAX® leads to greater use of AOM and greater 21 
adherence, in women at high fracture risk, compared with usual care.  22 
 23 
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Osteoporosis risk assessment has advanced markedly in recent decades. The introduction of an 2 
operational definition of osteoporosis based on dual-energy X-ray absorptiometry (DXA) bone mineral 3 
density (BMD) by the World Health Organisation in the mid-1990s permitted identification of those at 4 
risk of fracture due to a reduced bone mass.[1] Recognition of the contribution of risk factors other 5 
than BMD, and the latter’s sub-optimal sensitivity for fracture prediction, led to the development of 6 
the FRAX® Fracture Risk Calculation tool. This uses a small number of intuitively reasonable and 7 
clinically readily available risk factors, together with femoral neck BMD if measured, to calculate an 8 
individualised 10-year probability of fracture, integrating risk of fracture with the competing hazard 9 
of death.[2]  10 
There are around 120 guidelines internationally that use the FRAX® tool.[3] Whilst the majority of 11 
guidelines have suggested approaches based on opportunistic case finding (for example the earlier UK 12 
Royal College of Physicians Guidelines and subsequently the National Osteoporosis Guideline 13 
Group[4]), the effectiveness and cost effectiveness of systematic screening has recently been 14 
demonstrated in the SCOOP trial.[5-8] Although there was no effect on fractures overall, in this trial, 15 
identification in primary care of older women at high risk of fracture (using FRAX® probability of hip 16 
fracture and subsequent recommendation for treatment) led to a 28% reduction in hip fractures over 17 
5 years compared with usual care.[6] Such advances must be viewed in the context of an international 18 
backdrop of declining medication use for both primary and secondary prevention for a variety of 19 
reasons but, critically, this makes interventions that optimise identification and treatment of patients 20 
at high fracture risk a global imperative.[9, 10]  21 
Whilst the SCOOP trial demonstrated that the intervention was acceptable and associated with 22 
increased medication initiation, a key component of efficacy is adherence (proportion of prescribed 23 
doses taken).[11, 12] In this post hoc exploratory study, we used existing data from the trial to 24 
investigate whether the SCOOP screening intervention was associated with increased self-reported 25 
adherence to anti-osteoporosis medication, and explored the determinants thereof. 26 
 27 
Materials and methods 28 
Study Design 29 
The ‘Screening of older women for prevention of fracture’ (SCOOP) study was a pragmatic, unblinded, 30 
two group, parallel randomised controlled trial to assess the effectiveness of screening to prevent 31 
fractures in older women. Details of the study have been published:[5] in brief, women aged 70-85 32 
5 
 
years were invited from primary care lists within seven UK centres; those responding were randomly 1 
assigned (1:1) to either a screening arm or a control arm. Randomisation was completed using an 2 
online, web-based system, and was set up by an independent database programme from the Norwich 3 
Clinical Trials Unit. In the screening arm, the FRAX® risk algorithm was used to determine baseline 4 
fracture risk (10-year probability of hip fracture) and those participants identified as being at moderate 5 
or high risk of fracture (using an age-dependent threshold, equivalent to the 10-year probability 6 
consequent to the presence of a previous fracture) had a DXA scan to obtain femoral neck bone 7 
mineral density (BMD). Their 10-year hip fracture probability was then recalculated including BMD. 8 
Those in the control arm received usual UK NHS care (opportunistic discussion of osteoporosis). In the 9 
screening arm, anti-osteoporosis medication was recommended to those participants found to be at 10 
high risk of fracture after inclusion of the BMD measurement in FRAX®. If required anti-osteoporosis 11 
mediation was issued by the study participants’ Primary Care physicians, in accordance with national 12 
guidance from the United Kingdom Royal College of Physicians and National Osteoporosis Guideline 13 
Group.[4]  14 
Data collection 15 
Self-reported anti-osteoporosis medication (AOM) use was obtained by postal questionnaire at 6, 12, 16 
24, 36, 48 and 60 months after randomisation for both study arms. Since it was not possible to assess 17 
whether medicines were actually taken, prescription adherence was assessed over the full 60-month 18 
study duration, and calculated as the percentage of subsequent time points at which the participants 19 
reported taking anti-osteoporosis medication, following a positive report of medication use at the 6 20 
month (or subsequent) questionnaire.  21 
 22 
Statistical analysis 23 
Characteristics of participants were described using means and standard deviations (SD) for normally 24 
distributed continuous variables, and using medians and inter-quartile ranges for skewed variables. 25 
Frequencies and percentages were used to summarise binary and categorical variables. Study 26 
participants were then grouped into two adherence groups,[13] good adherence (defined as 27 
medication adherence 80% or more) or poor adherence (defined as less than 80% adherence). Logistic 28 
regression was used to investigate whether FRAX® probability or FRAX® component clinical risk factors 29 
at baseline were associated with adherence. Since some patients may have been commenced on 30 
treatment as a result of experiencing a fracture during follow-up rather than as a direct result of the 31 
screening, we also examined initiation and adherence firstly amongst those who did not experience 32 
an incident (post-baseline) fracture before initiation of treatment, and secondly amongst the group 33 
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who did experience an incident fracture before commencing medication. Given that information on 1 
fractures and medication was obtained at the follow-up questionnaires, it was not possible to establish 2 
the order of such events prior to 6 months, and so analysis of initiation at 6 months assumes no prior 3 
fracture between baseline and this time point. The analysis based on medication initiation after an 4 
incident fracture thus only used follow-up from 12 months onwards.  All analyses were undertaken 5 
using Stata 14.[14]   6 
Full ethics approval was obtained from the North Western – Haydock Research Ethics Committee of 7 
England in September 2007 (REC 07/H1010/70). The trial was registered on the International Standard 8 
Randomised Controlled Trial Register in June 2007 (ISRCTN55814835).  All participants gave written, 9 
informed consent. 10 
Results  11 
Participant characteristics 12 
A total of 12,483 participants were randomised: 6,233 women to the screening arm and 6,250 to the 13 
control arm.  Overall, the mean age was 75.6 years and the median body mass index (BMI) 26kg/m2.  14 
At baseline, the median FRAX® hip fracture probability of all participants calculated without BMD was 15 
6.3% and of those with BMD measured the mean T-score was -1.7. Just under 5% of participants 16 
reported smoking at baseline, 3.6% drank more than 3 units of alcohol a day and 10% of participants 17 
reported a parental history of hip fracture.  Characteristics of all study participants are presented by 18 
randomisation group in Table 1, demonstrating that the baseline characteristics were well balanced 19 
between the two groups. Of those in the screening arm, 14.3% were classified at high risk of fracture 20 
based on FRAX® 10-year hip fracture probability (Figure 1). Over the 60 month study duration, 15.7% 21 
reported an incident fracture.  22 
Medication initiation by time and group 23 
At six months, 7.2% of the whole study population reported using anti-osteoporosis medication 24 
(AOM)(Figure 2). Of those study participants in the screening arm identified to be at high risk of 25 
fracture, 75.8% were taking AOM compared with only 2.0% in the control arm overall. By 60 months, 26 
11.5% of all study population were taking an AOM, with 56.6% of those identified as at high risk of 27 
fracture reporting taking medication, compared with 9.7% in the control arm overall. 28 
Medication adherence 29 
Of the 823 SCOOP participants who self-reported AOM use at 6 months (and assumed not to have 30 
experienced a fracture between the baseline assessment and the 6 month questionnaire), 79.2% 31 
(n=652) remained on treatment at 12 months, 65.0% (n=535) at 24 months and 34.9% (n=287) 32 
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remained on treatment for the entire 60 month duration of follow-up. Similar patterns of treatment 1 
decay were seen when study participants commenced medication at later study time points (restricted 2 
to those individuals who had not experienced a fracture between baseline assessment and treatment 3 
commencement, demonstrated graphically in Figure 3a). Of the 628 study participants who were 4 
identified at high risk of fracture in the screening arm and reported treatment at 6 months, 38.2% 5 
(n=240) remained on treatment for the 60 month duration; the respective figure for the control group 6 
was 21.6% (n=25).  7 
Medication adherence following initiation after an incident fracture 8 
Figure 3b demonstrates the decay in adherence following initiation of medication after an incident 9 
fracture. At 12 months, 30 participants had initiated treatment following a post-baseline fracture prior 10 
to this assessment. 96.7% (n=29) were still adherent at 24 months and 36.7% (n=11) at 60 months. 11 
Patterns of adherence decay were similar with treatment initiation at later time points. 12 
Baseline characteristics associated with 60 month adherence 13 
As expected, the components of the FRAX® score were associated with initiation of treatment, and on 14 
univariate modelling, on average the odds of having good adherence to AOM reduced with each year 15 
higher age[OR 0.96 (95%CI: 0.93, 0.99), p<0.01], whereas the odds of having good adherence to AOM 16 
over the five-year study duration was higher in those with a history of a  parental hip fracture [OR 1.67 17 
(95%CI: 1.23, 2.26), p<0.01] (Table 2). In the screening arm, participants who underwent a DXA 18 
assessment had odds nearly twice as high as those without a DXA assessment for reporting good 19 
adherence to AOM [OR 1.89 (95%CI: 1.33, 2.68), p<0.01] and participants who were identified at high 20 
fracture risk after inclusion of the BMD measurement in FRAX® had higher odds of good adherence 21 
[OR 2.80 (95%CI: 1.21, 6.50), p=0.02].  22 
 23 
Discussion 24 
In this pragmatic randomised trial of systematic screening for fracture risk in older women, using 25 
FRAX® in primary care, the screening intervention was associated with greater rates of AOM 26 
prescription, and self-reported medication adherence, than that those observed with usual NHS care. 27 
Furthermore, greater adherence was associated with younger age and a history of parental hip 28 
fracture. Since further routine FRAX® calculation and BMD scanning were not part of the protocol, our 29 
findings highlight the importance of the initial screening assessment. 30 
To our knowledge, this is the first study to demonstrate the benefit of systematic screening on 31 
osteoporosis medication adherence. Good adherence to osteoporosis medications is clearly essential, 32 
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demonstrated by the reduced efficacy of medications such as alendronic acid when prescription 1 
regimens are poorly followed.[15, 16] Similar to the prevention of many other common chronic non-2 
communicable diseases, adherence to bisphosphonates is generally sub-optimal, with reported rates 3 
as low as 40%.[11, 17, 18] Reasons for poor adherence are not well understood, but there is evidence 4 
from a large, international cohort study of  60,000 older women, that appreciation of individual risk is 5 
variable, and the majority of women underestimate their risk of fracture, even having experienced a 6 
prior fracture.[19, 20] In recent years, there has been concern over rare serious side effects of long-7 
term antiresorptive treatment.[9, 10] These have often been excessively reported in the media (and 8 
sometimes also in the scientific press); in particular, communication of the appropriate balance 9 
between risk and benefit has usually not occurred, especially in the context of the global media.[21, 10 
22]  It is notable that rates of medication use for both primary and secondary prevention appear to be 11 
falling over recent years.[10, 21, 23-25] 12 
Previous investigations have explored a variety of methods to improve medication adherence. These 13 
have included measurement of bone turnover markers, BMD, nurse/practitioner review, and 14 
educational programmes, with the aim of providing positive feedback and monitoring of progress.[11, 15 
16, 26] However, there are clear resource implications for such interventions, and the value of specific 16 
measures such as bone turnover markers over and above simple contact with a health professional is 17 
not certain.[11] It is therefore notable that the present screening intervention, undertaken in primary 18 
care using the FRAX® tool, led not just to increased uptake of medication but also to improved 19 
adherence compared with those individuals prescribed medication in the usual care group. 20 
That family history of hip fracture was associated with better adherence is easily comprehensible, 21 
although the lack of association with prior fracture is perhaps counterintuitive, albeit consistent with 22 
findings from the GLOW study.[19] Increased adherence in those who underwent BMD testing may 23 
simply reflect collinearity with other risk variables, since these individuals were by definition at 24 
moderate to high fracture risk, or potentially a positive effect of the DXA scan on adherence. Our 25 
analysis explored adherence amongst those individuals who had (or had not) experienced a fracture 26 
after the baseline assessment, but before initiation of medication, and suggested perhaps greater 27 
adherence in the first 12 months after initiation for the post-incident fracture group commencing 28 
medication at one year. However, the percent adherence was similar at the end of the study, and the 29 
numbers were not large enough to permit a logistic regression analysis based on incident fracture. We 30 
were unable to reliably assess the temporal relationships between medication initiation and fracture 31 
occurrence in the first 6 months of follow-up, and so assumed that medication initiation preceded a 32 
fracture event during this period. The validity of this assumption cannot be tested, but given the 33 
findings in relation to medication adherence for initiation following a fracture in our subsequent 34 
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analyses, it is possible that the balance of fractures either side of the 6 month questionnaire could 1 
have influenced our results. 2 
Our finding of lower adherence at older ages may reflect a higher burden of comorbidity and 3 
associated medications. Indeed, key perceptions that influence older women with regard to 4 
adherence to such medications was investigated in a qualitative study, nested within the SCOOP 5 
trial[27]. In this investigation of 30 women aged 70-85 years who were offered anti-osteoporosis 6 
medication, there were no overall predictors of adherence across two years of assessment. The 7 
women’s perceptions and motivations related to persistence with medication were influenced by 8 
factors such as their understanding of adherence/non-adherence, motivations and self-care, 9 
appraising/prioritising risk, anticipating/managing side effects and issues relating to problems of 10 
understanding and decision-making. Importantly, those engaged with supportive professionals better 11 
tolerated/overcame potential barriers posed by side effects.[27] The present results complement 12 
these detailed findings from interviews in a small group of women, by elucidating overarching 13 
predictors of adherence across the whole trial population. 14 
We studied a unique multicentre, primary care-based UK randomised controlled trial with 15 
comprehensive assessment of medication use. However, there are some limitations that could should 16 
be considered in the interpretation of our findings. Firstly, medication use was obtained by self-report 17 
questionnaire at specific time points, and was not validated by semi-objective measures such as pill 18 
counts. It is possible that transient use was therefore underestimated, though if anything this would 19 
tend to reduce the chances of observing differences between the groups. Furthermore, self-report 20 
may lead to over-estimation of adherence compared with pill counts, but it is likely, given the context 21 
of participation in a trial for the prevention of osteoporotic fracture, that participants were motivated 22 
to take treatment[28].  The self-report question within the SCOOP postal questionnaire asked study 23 
participants whether they were currently taking AOM, and no detail of the types of medication were 24 
captured at this time. AOM were prescribed by General Practitioners and so the vast majority are likely 25 
to be oral bisphonates; however in this study we are unable to assess whether the type of medication 26 
impacted the level of adherence: for example we could not readily assess any influence of annual 27 
intravenous zoledronate prescription on our findings. Additionally, we lacked information relating to 28 
new prescriptions of corticosteroids. Secondly, we have limited capacity to explore psychosocial 29 
aspects related to adherence, but these have been investigated previously in subsets of the trial.[27, 30 
29] Thirdly, the study population consisted of older women, limiting the generalisability of these 31 
findings to younger women and to men, and we had limited information about aspects of clinical care 32 
in the control group, for example, use of DXA scanning. Finally, it is possible that trial participants were 33 
somewhat healthier than the general population. This “healthy selection effect” may limit 34 
10 
 
generalisability, but should not materially influence differences between the two groups, since 1 
participants were randomly allocated to screening or usual care. Further studies in a population of 2 
men and women, in which in-depth analysis examining whether different AOM medications had 3 
significantly differing levels of adherence and treatment adherence captured using more sophisticated 4 
methods would be warranted.  5 
In conclusion, systematic screening for fracture risk using FRAX® in primary care led to increased use 6 
of, and adherence to, anti-osteoporosis medications, compared with usual care. Taken with recent 7 
evidence that this intervention results in a reduction in risk of hip fracture, the present findings further 8 
support the use of systematic screening approaches for fracture prevention. 9 
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Figure legends 1 
 2 
Figure 1:  Consort diagram 3 
 4 
Figure 2:  Anti-osteoporosis medication use over the duration of the SCOOP trial by randomisation 5 
group [screening (intervention) vs usual care (control)]. 6 
 7 
Figure 3a:  Anti-osteoporosis medication (AOM) adherence over the 5 year duration of the SCOOP trial 8 
in study participants who initiated treatment, and who had not experienced a fracture between 9 
baseline and commencement of medication. (Calculated as the percent study participants who 10 
remained on AOM at each subsequent timepoint having initiated treatment at each index timepoint.) 11 
 12 
Figure 3b:  Anti-osteoporosis medication (AOM) adherence over the 5 year duration of the SCOOP 13 
trial in study participants who initiated treatment after the occurrence of a fracture post-baseline. 14 
(Calculated as the percent study participants who remained on AOM at each subsequent timepoint 15 
having initiated treatment at each index timepoint.) 16 
16 
 
Table 1: Participant characteristics at baseline assessment. 
 Screening arm Control arm 
Characteristic n Mean SD n Mean SD 
Age (years) 6233 75.5 4.2 6250 75.6 4.1 
Height (cm) 6233 160.7 6.3 6250 160.9 6.4 








BMI (kg/m2) 6233 26.0 23.4-29.3 6250 26.1 23.4-29.2 
Weight (kg) 6233 67.1 60.3-76.2 6250 67.6 60.3-76.2 
FRAX® Probability (hip without BMD) 6233 6.3 3.8-10.5 6250 6.3 3.8-10.5 
 n % n % 
Parental history of hip fracture  585 9.4 577 9.2 
Incident fracture (post baseline) 956 15.3 1010 16.2 
Prior fracture b 1399 22.7 1463 23.6 
Smoker 291 4.7 290 4.6 
Taken corticosteroids for more than a 
few weeks 
316 5.1 312 5.0 
Rheumatoid arthritis 426 6.8 410 6.6 
> 3 units of alcohol a day 219 3.5 225 3.6 
Risk category a     
Low 5342 85.7 - - 
High 891 14.3 - - 
a Risk categorisation undertaken in intervention arm only; FRAX® high risk threshold 70-74 years 5.24%, 75-79 years 6.87%, 80-84 years 8.52%, 85 years 8.99% 







Table 2: Univariate associations between participant characteristics (at baseline) and adherence to anti-osteoporosis medication (AOM) over the 5 year 
follow-up period (Logistic regression). 
 
 




95% CI p-value 
Age (years)a 0.96 (0.93,0.99) 0.01 
Weight [log(kg)]b 1.15 (0.52,2.51) 0.74 
Height (cm)c 1.01 (0.99,1.03) 0.42 
Prior fracture (Y/N) 0.89 (0.67,1.17) 0.40 
Parent broken hip (Y/N) 1.67 (1.23,2.26) <0.01 
Smoker (Y/N) 1.00 (0.61,1.64) 1.00 
Taken corticosteroids (Y/N) 0.81 (0.54,1.23) 0.32 
Rheumatoid arthritis (Y/N) 0.80 (0.50,1.27) 0.34 
Alcohol consumption (Y/N) 0.57 (0.32,1.03) 0.06 
DXA Scan (Y/N) 1.89 (1.33, 2.68) <0.01 
Total hip BMD T-score (SD) 1.02 (0.82,1.27) 0.85 
Incident fracture (post baseline) (Y/N) 1.03 (0.76,1.40) 0.86 
FRAX® risk category (High/Low)d 2.80 (1.21,6.50) 0.02 
a OR for each year higher in age; b OR for each log(kg) increase in weight; c OR for each cm increase in height; 
 d in a subgroup of study participants with a FRAX® category using BMD 
 
 
